Plasma HIV-RNA is the key determinant of long-term antibody persistence after yellow fever immunization in a cohort of 364 HIV-infected patients

Journal of Acquired Immune Deficiency Syndromes

Volumn 59, Issue 4, 2012, Pages 360-367

  Pacanowski, Jérôme ^a   Lacombe, Karine ^a,b,c   Campa, Pauline ^a   Dabrowska, Magdalena ^a,d   Poveda, Jean Dominique ^e   Meynard, Jean Luc ^a   Poirot, Jean Louis ^a   Fonquernie, Laurent ^a   Girard, Pierre Marie ^a,b,c  

^a HÔPITAL SAINT ANTOINE   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c INSERM   (France)

^d MEDICAL UNIVERSITY OF WARSAW   (Poland)

^e LABORATOIRE CERBA   (France)

Author keywords

HIV; Immunization; Yellow fever vaccination

Indexed keywords

NEUTRALIZING ANTIBODY; VIRUS RNA; YELLOW FEVER VACCINE;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNIZATION; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; THERAPY DELAY; VACCINE FAILURE; VIRUS REPLICATION; YELLOW FEVER;

ADULT; ANTIBODIES, VIRAL; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MALE; PROSPECTIVE STUDIES; RISK FACTORS; RNA, VIRAL; VIRAL LOAD; YELLOW FEVER VACCINE; YOUNG ADULT;

EID: 84859749770     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318249de59     Document Type: Article

References (28)

1. Robertson SE, Hull BP, Tomori O, et al. Yellow fever: a decade of reemergence. JAMA. 1996;276:1157-1162. (Pubitemid 26329743)
2. Staples JE, Monath TP. Yellow fever: 100 years of discovery. JAMA. 2008;300:960-962.
3. Poland JD, Calisher CH, Monath TP, et al. Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine. Bull World Health Organ. 1981;59:895-900. (Pubitemid 12155776)
4. Khromava AY, Eidex RB, Weld LH, et al. Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events. Vaccine. 2005;23:3256-3263. (Pubitemid 40523118)
5. Veit O, Hatz C, Niedrig M, et al. Yellow fever vaccination in HIVinfected patients. HIV Ther. 2010;4:17-26.
6. Kengsakul K, Sathirapongsasuti K, Punyagupta S. Fatal myeloencephalitis following yellow fever vaccination in a case with HIV infection. J Med Assoc Thailand (Chotmaihet thangphaet). 2002;85:131-134.
7. Cetron MS, Marfin AA, Julian KG, et al. Yellow fever vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2002. MMWR Recomm Rep. 2002;51(RR-17):1-11; quiz CE1-4.
8. Goujon C, Tohr M, Feuillie V, et al. Good tolerance and efficacy of yellow fever vaccine among subjects carriers of HIV [abstract 32]. Presented at: Program and abstracts of the 4th International Conference on Travel Medicine; 1995; Acapulco, Mexico.
9. Sibailly TS, Wiktor SZ, Tsai TF, et al. Poor antibody response to yellow fever vaccination in children infected with human immunodeficiency virus type 1. Pediatr infect Dis J. 1997;16:1177-1179.
10. Receveur MC, Thiebaut R, Vedy S, et al. Yellow fever vaccination of human immunodeficiency virus-infected patients: report of 2 cases. ClinInfect Dis. 2000;31:E7-E8.
11. Tattevin P, Depatureaux AG, Chapplain JM, et al. Yellow fever vaccine is safe and effective in HIV-infected patients. AIDS. 2004;18:825-827. (Pubitemid 38535017)
12. Pistone T, Verdiáre CH, Receveur MC, et al. Immunogenicity and tolerability of yellow fever vaccination in 23 French HIV-infected patients. Curr HIV Res. 2010;8:461-466.
13. Veit O, Niedrig M, Chapuis-Taillard C, et al. Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients. Clin Infect Dis. 2009;48:659-666.
14. Niedrig M, Lademann M, Emmerich P, et al. Assessment of IgG antibodies against yellow fever virus after vaccination with 17D by different assays: neutralization test, haemagglutination inhibition test, immunofluorescence assay and ELISA. Trop Med Int Health. 1999;4:867-871. (Pubitemid 30041042)
15. Lang J, Zuckerman J, Clarke P, et al. Comparison of the immunogenicity and safety of two 17D yellow fever vaccines. Am J Trop Med Hygiene.1999;60:1045- 1050. (Pubitemid 29296235)
16. Overton ET, Nurutdinova D, Sungkanuparph S, et al. Predictors of immunity after hepatitis A vaccination in HIV-infected persons. J Viral Hepat. 2007;14:189-193.
17. Laurence JC. Hepatitis A and B immunizations of individuals infected with human immunodeficiency virus. Am J Med. 2005;118(suppl 10A):75S-83S. (Pubitemid 41552437)
18. Overton ET, Sungkanuparph S, Powderly WG, et al. Undetectable plasma HIV RNA load predicts success after hepatitis B vaccination in HIV-infected persons. Clin Infect Dis. 2005;41:1045-1048. (Pubitemid 41368231)
19. Bailey CL, Smith V, Sands M. Hepatitis B vaccine: a seven-year study of adherence to the immunization guidelines and efficacy in HIV-1-positive adults. Int J Infect Dis. 2008;12:E77-E83.
20. Puthanakit T, Aurpibul L, Yoksan S, et al. Japanese encephalitis vaccination in HIV-infected children with immune recovery after highly active antiretroviral therapy. Vaccine. 2007;25:8257-8261. (Pubitemid 350087385)
21. Levin MJ, Gershon AA, Weinberg A, et al. Immunization of HIV-infected children with varicella vaccine. J Pediatr. 2001;139:305-310. (Pubitemid 32721722)
22. Evison J, Farese S, Seitz M, et al. Randomized, double-blind comparative trial of subunit and virosomal influenza vaccines for immunocompromised patients. Clin Infect Dis. 2009;48:1402-1412.
23. Hung CC, Chang SY, Su CT, et al. A 5-year longitudinal follow-up study of serological responses to 23-valent pneumococcal polysaccharide vaccination among patients with HIV infection who received highly active antiretroviral therapy. HIV Med. 2010;11:54-63.
24. Hepburn MJ, Kortepeter MG, Pittman PR, et al. Neutralizing antibody response to booster vaccination with the 17d yellow fever vaccine. Vaccine. 2006;24:2843-2849.
25. Roukens AH, Vossen AC, Bredenbeek PJ, et al. Intradermally administered yellow fever vaccine at reduced dose induces a protective immune response: a randomized controlled non-inferiority trial. PloS One. 2008;3:e1993.
26. Miller JD, van der Most RG, Akondy RS, et al. Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity. 2008;28:710-722.
27. Pulendran B, Miller J, Querec TD, et al. Case of yellow fever vaccine- associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes. J Infect Dis. 2008;198:500-507.
28. Roukens AH, Visser LG, Kroon FP. A note of caution on yellow fever vaccination during maraviroc treatment: a hypothesis on a potential dangerousinteraction. AIDS. 2009;23:542-543.